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Alterations in epithelial mucin expression are associated with carcinogenesis, but there are few data in biliary tract cancer (BTC). In
pancreatic malignancy, MUC4 is a diagnostic and prognostic tumour marker, whereas MUC5AC has been proposed as a sensitive
serological marker for BTC. We assessed MUC4 and MUC5AC expression in (i) prospectively collected bile and serum specimens
from 72 patients with biliary obstruction (39 BTC) by real-time reverse transcriptase–PCR (qPCR) and western blot analysis, and (ii)
79 archived biliary tissues (69 BTC) by immunohistochemistry. In bile, MUC4 protein was detected in 27% of BTC and 29% of
primary sclerosing cholangitis (PSC) cases, but not in other benign and malignant biliary diseases (Po0.01 and P¼0.06). qPCR
revealed a 1.9-fold increased MUC4 mRNA expression in BTC patients’ bile compared with benign disease. In archived tissues,
MUC4 protein was detected in 37% of BTC but in none of the benign samples (P¼0.03). In serum, MUC5AC was found exclusively
in BTC and PSC sera (44% and 13%, respectively; Po0.001 for BTC vs non-BTC) and correlated negatively with BTC survival. Biliary
MUC4 and serum MUC5AC are highly specific tumour-associated mucins that may be useful in the diagnosis and formulation of
therapeutic strategies in BTC.
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Biliary tract cancer (BTC; gallbladder or cholangiocarcinoma) has
a poor prognosis. Surgery is associated with 5-year survival rates
of 24–40% (Seyama and Makuuchi, 2007), but more than 80% of
patients are considered unresectable at the time of diagnosis
(Jarnagin et al, 2001) and have a median survival of approximately
6–9 months (Khan et al, 2002).
The early detection of BTC remains a clinical challenge. Even in
advanced disease, tissue diagnosis is often difficult and the
sensitivity is low (Khan et al, 2002; Malhi and Gores, 2006). The
most commonly used BTC tumour markers, carbohydrate antigen
(CA)19-9 and carcinoembryonic antigen, are of limited use in
patients with indeterminate biliary strictures (Nehls et al, 2004)
and there is a need for better diagnostic tests.
Alterations in the epithelial mucin glycoprotein profile are
associated with malignant disease. In pancreatic tissue, of the same
embryological origin as biliary epithelium, MUC4 expression is
absent in benign disease, but is present in 90% of adenocarcino-
mas and is associated with reduced survival (Moniaux et al, 2004a;
Saitou et al, 2005). In BTC, recent studies from east Asia suggest
that MUC4, as well as MUC5AC, may be suitable candidate tumour
markers (Shibahara et al, 2004; Tamada et al, 2006). In northern
Thailand, a region with a high incidence of BTC, MUC5AC protein
was detected in the sera of 63% of 179 patients with BTC, but in
none of 74 healthy controls (Wongkham et al, 2003).
To date, there have been no studies of serum MUC5AC in other
BTC patient populations and no prospective studies of mucin
expression in bile. To test the hypothesis that MUC4 and MUC5AC
are tumour-associated mucins in BTC, we characterised expression
of MUC4, MUC5AC and MUC5B (present in normal biliary
epithelium) by immunohistochemistry in archival biliary tissue
and by western blotting and real-time reverse transcriptase–
polymerase chain reaction (rt RT–PCR) in bile and serum
samples.
MATERIALS AND METHODS
Patients
Over a 12-month period, bile and serum samples were collected
prospectively from 72 adult patients undergoing endoscopic
retrograde cholangiopancreatography (ERCP) or percutaneous
transhepatic cholangiography for evaluation of indeterminate or
established benign and malignant biliary tract strictures. A
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sdiagnosis of malignancy was made by positive cytology and/or
biopsy, or evidence of disease progression on imaging. Benign
disease was established by negative pathology and a minimum of
12-month clinical follow-up.
Bile samples (5ml) were aspirated proximal to the stricture via a
standard ERCP catheter, transferred into cryovials and placed
immediately in liquid nitrogen. All clinical specimens were stored
at  701C.
The study was approved by the Joint UCLH/UCL Committee on
the Ethics of Human Research (reference no. 04/0028), and all
patients gave written informed consent.
Mucin glycoprotein concentrations in bile and serum
Agarose (2%) gel electrophoresis (with 0.1% sodium dodecyl
sulphate (SDS)) was performed using 10mM 1,4-dithiothreitol
(DTT) (all from Sigma-Aldrich, Steinheim, Germany). Freshly
thawed bile samples were diluted 1:2 in 1% SDS dissolving buffer
(40mM Tris-acetate, 1mM EDTA, 30% glycerol, 0.002% bromo-
phenol), and a final volume of 30ml was loaded per well. Bile
protein concentrations were measured using the bicinchoninic
acid protein assay (Pierce, Rockford, IL, USA). Serum samples
were diluted 1:2 in a 2% SDS dissolving buffer (as above) and 20ml
loaded per well. After electrophoresis, polyvinylidene difluoride
membrane (Hybondt-P; Amersham Pharmacia Biotech, Little
Chalfont, UK) vacuum blotting (in 0.6 M sodium chloride/60mM
sodium citrate transfer buffer; suction pressure of 40mbar) was
performed. We used the following primary antibodies: two
monoclonal MUC4 mouse antibodies, clone 8G7 (Moniaux et al,
2004b), detecting a 16-amino-acid epitope in the tandem repeat
ectodomain (Batra’s Lab; concentration 1:1000), and clone 1G8
(Zhang et al, 2005), directed towards an epitope from the
membrane-associated subunit (Zymed
s-affinity purified; Invitrogen,
Paisley, UK; also supplied by K Carraway, Miami, FL, USA;
concentration 1:400), a single polyclonal MUC5AC rabbit antiser-
um, Lum5-1 EU-batch (Hovenberg et al, 1996) (supplied by I
Carlstedt, Lund, Sweden; concentration 1:600), and a single
monoclonal mouse MUC5B antibody, clone EU-MUC5Ba (Rousseau
et al, 2003) (concentration 1:200), both detecting peptide sequences
in non-glycosylated domains in the main tandem repeat regions.
Four-hour first antibody incubation was followed by phosphate-
buffered saline (PBS) washes (plus 0.05% Tween
s 20), 1-h
incubation with the appropriate secondary antibodies (rabbit
anti-mouse or swine anti-rabbit (Dako A/S, Glostrup, Denmark)),
further PBS/Tween washes and final chemoluminescence detection
(ECLt-Western-blotting-detection reagents; Amersham Biosciences,
Little Chalfont, UK). The strength of the bands was assessed in
relation to the positive control samples (breast milk (1:100
dilution) for MUC4, sputum (1:10) for MUC5AC, saliva (1:200)
for MUC5B), using a semiquantitative assessment score (negative,
þ, þþand þþþ), as shown in Figure 1. Band signals of one
þ strength or greater were considered positive in the analysis.
Mucin mRNA expression (by rt RT–PCR)
RNA extraction Total RNA was extracted from 1ml aliquots of
thawed bile using TRI reagent (Ambion Inc., Austin, TX, USA),
according to the manufacturer’s protocol (two volumes of TRI
reagents per one volume of bile). To remove contaminating DNA,
RNA samples were further (a) DNase-I-digested using Turbo-
DNase-free kit (Ambion Inc.) and (b) purified using RNeasy-Mini-
Elute kit (Qiagen Ltd, Crawley, UK).
cDNA synthesis Purified total RNA samples were reverse-
transcribed using iScriptt-Select-cDNA-Synthesis kit (Bio-Rad
Laboratories, Hemel Hempstead, UK), according to the manufac-
turer’s protocol. Reactions were primed with random hexamers;
the total volume per reaction was 20ml.
Real-time PCR amplification PCR was performed in a total
volume of 25ml using qPCR-Master-Mix-plus-dNTP kit (Euro-
genetec, Southampton, UK) and analysed on an Applied Biosys-
tems 7500 Real-Time PCR system (Applied Biosystems, Foster
City, CA, USA). A 1ml portion of cDNA per sample was used as
template. All amplifications were performed in duplicate. The
thermal cycling conditions included 501C for 2min and 951C for
10min, followed by 40 cycles of 951C for 15s and 601C for 1min.
Primers and probes Primers and probe sets for MUC4 and
MUC5AC were sourced from published reports (Argu ¨eso et al,
2002) and synthesised by Eurogenetec:
MUC4 (GenBankt accession number AF058803): forward
primer 50-1499GCCCAAGCTACAGTGTGACTCA1520-30; reverse
primer 50-1600ATGGTGCCGTTGTAATTTGTTGT1578-30; probe
50(Yakima Yellow)-1532CGGCCACATCCCCATCTTCTTCAC1555
(BHQ-1)-30; located in the C-terminal section (exon 25) of MUC4.
MUC5AC (GenBank accession number Z48314): forward primer
50-273TCCACCATATACCGCCACAGA293-30; reverse primer 50-
375TGGACGGACAGTCACTGTCAAC354-30; probe 50(Dragon Fly)-
297CTCGCTGGCCATTGCTATTATGCCC321(BHQ-2)-30; located
in the first exon after the tandem repeat domain of MUC5AC.
The endogenous human glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) control reagents were purchased from Applied
Biosystems.
Real-time RT–PCR Quantitative values for mucin expression
were obtained by TaqMan
s methodology from identification of
the cycling point when PCR product is detectable (threshold cycle
or CT value). To normalise the amount of total RNA present in
each reaction, we amplified the housekeeping gene GAPDH.
Results are expressed as levels of MUC(s) mRNA, relative to
normal bile samples (the calibrator), chosen to represent 1 
expression of this gene. The pathological bile samples express
n-fold MUC(s) mRNA relative to the calibrator. The amount of
target, normalised to an endogenous reference (GAPDH) and
relative to the calibrator, is defined by the double-delta CT (DDCT)
method as described by Livak and Schmittgen (2001). To ascertain
the origin of RNA in bile, we tested samples for expression of
CK-19 and CD45, markers for biliary epithelium and leukocytes,
respectively.
Mucin immunohistochemistry
Archival formalin-fixed biliary tissue from 69 patients with BTC
and 10 without biliary disease were identified from the University
College Hospital tissue bank. The following monoclonal antibodies
were employed: 1G8 clone against MUC4 (see above), 21M1 clone
against MUC5AC (Nollet et al, 2002) (supplied by J Bara, Paris,
France, which detects the vWF-A3uD4 domain) and EU-MUC5Bb
clone against MUC5B (see above). The following normal tissues
were used as positive antibody controls: stomach for MUC5AC,
bronchus for MUC4 and MUC5B.
Paraffin sections of 3mm were dewaxed with Histocleart (RA
Lamb, Eastbourne, UK) and dehydrated in graded alcohols.
Endogenous peroxidase was blocked with 1.5% hydrogen peroxide
diluted in methanol for 10min, followed by a reduction step in
10mM DTT (Sigma-Aldrich) in 0.1 M Tris/HCl buffer, pH 8, at 251C
for 30min and treatment with 0.025 M of the alkylating agent
iodoacetamide (Sigma-Aldrich) in 0.1 M Tris/HCl, pH 8.0, for
another 30min. No reduction was required for MUC4. Sections
were then washed with Tris-buffered saline (TBS). For improved
antigen retrieval for MUC4 and MUC5B stainings, tissues were
microwaved in 0.01 M citrate buffer, pH 6, on high power for
10min. For MU5AC staining, tissue was subjected to trypsinisation
for 5min at 371C with 50mg chymotrypsin (Sigma-Aldrich)
dissolved in 1mM calcium chloride, pH 7.8. Liver tissues were
blocked for endogenous biotin using Dako’s biotin-blocking kit
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s(Dako A/S). Vectastain Elite-ABC-mouse-IgG kit (Vector Labora-
tories, Burlingame, CA, USA) was used for immunohistochemical
staining. Sections were washed again in TBS and incubated in
normal horse serum for 20min. This was followed by primary
antibody exposure: 1G8 (MUC4) diluted at 1:250 (purified ascites;
0.5mgml
 1); 21M1 (MUC5AC) diluted at 1:1000000 (ascites
fluid); and EU-MUC5Bb (MUC5B) diluted at 1:100 (culture
supernatant). All antibodies were incubated for 1h at 251C.
Sections were then washed in TBS, and a horse anti-mouse
biotinylated secondary antibody was applied for 30min, followed
by 30-min incubation in horseradish peroxidase-conjugated
avidin–biotin complex. Sections were developed in diaminoben-
zidine (Dako A/S) and counterstained in haematoxylin.
All slides were assessed by an experienced pancreaticobiliary
histopathologist (MD), applying a semiquantitative scoring system
(negative¼less than 5% of neoplastic cells stained positive,
þ¼5–20%, þþ¼20–50%, þþþ¼more than 50%), as used
in previous publications (Tamada et al, 2006) and shown in
Figure 1. High-expression samples (X20%) were considered
positive in the analysis.
Statistical analysis
Statistical analysis was performed using SPSS software, version
14.0 (SPSS Inc., Chicago, IL, USA). Numerical data were presented
as medians with ranges or as mean values with standard errors of
the mean. Intergroup comparisons were performed with Student’s
t-test for continuous variables and w
2 test for binary variables.
Survival was determined from the time of diagnosis to the time of
census on 30 June 2007. The Kaplan–Meier method was used for
survival rate estimates. Statistical significance between groups was
determined by log-rank or generalised Wilcoxon test. A P-value of
less than 0.05 was considered significant.
RESULTS
Clinical characteristics
Of the 72 patients from whom bile and blood samples were
collected prospectively, 39 patients (54%) were diagnosed with
BTC, 8 (11%) had non-BTC malignant conditions, 7 (10%) had
primary sclerosing cholangitis (PSC) and 18 (25%) had other
benign conditions.
Demographic, biochemical and clinical data of the patients, as
well as location and clinical T-staging (American Joint Committee
on Cancer (AJCC), 2002) of the BTC group, are summarised in
Table 1.
Complete survival data were available for all 39 BTC patients.
The overall median survival was 11.4 months (range: 0.3–46.3
months; 95% CI: 6.4–16.5 months) from the time of BTC
diagnosis.
Biliary MUC4 protein expression is highly BTC specific
Immunohistochemistry Archival tissue was obtained from 69
BTC patients (36 men and 33 women, median 69 years (range:
45–85 years), 46 perihilar CCA, 15 gallbladder carcinoma, 5 distal
extrahepatic and 3 intrahepatic CCA) and from 10 patients without
1:100
A
C D
B
Control
++ (20–50%)
+ (5–20%)
+++ (>50%)
+ ++ +++ +++
1:2 1:2 1:2 1:2
Figure 1 (A) Semiquantitative western blot assessment score – strength of band staining in relation to control sample – example with the monoclonal
8G7 clone MUC4 antibody (1:1000 dilution) on breast milk control (1:100 dilution) and four different bile samples (1:2 dilutions) (on 2% agarose (0.1%
SDS) gel and 10mM DTT). (B–D) Semiquantitative immunohistochemistry assessment score – percentage of positively stained malignant cells – example
with the monoclonal 1G8 clone MUC4 antibody (1:250 dilution) on three different biliary tissue specimens (at  400 magnification).
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sbiliary disease (7 women and 3 men, median age 67 years (range:
45–88 years), normal gallbladder and bile duct specimens from
pancreaticoduodenectomies). Fifty-seven (83%) of the malignant
specimens were from patients with advanced cancer stage
(XT3¼organ and/or large vascular structure invasion). Twelve
(17%) had known distant metastases at the time. The cancers were
graded as well differentiated in 12% (8 out of 69), moderately
differentiated in 71% (49 out of 69) and poorly differentiated in
17% (12 out of 69).
In BTC specimens, 37% (26 out of 69) showed MUC4 protein
expression, 10% (7 out of 69) MUC5AC and 2% (1 out of 69)
MUC5B. In benign biliary tissue, 80% (8 out of 10) showed MUC5B
expression, but neither MUC4 nor MUC5AC expression was seen
(Figure 2). Thus, MUC4 protein expression was associated with
BTC (P¼0.03), whereas MUC5B protein was more commonly
expressed in benign biliary disease (Po0.001). There was no
correlation between the strength of mucin staining and clinical
cancer stage for either MUC4 or MUC5AC.
Survival data were available for 94% (65 out of 69) of the
retrospective BTC cohort. The overall median survival was 9
months (range: 0.2–46.3 months; 95% CI: 4.5–13.4 months).
There was no survival difference between BTC patients with
MUC4-positive and MUC4-negative disease (P¼0.81). Equally,
there were no survival differences seen for MUC5AC- or MUC5B-
positive and negative BTC patients.
Western blot analysis Sixty-five bile samples (90%) were avail-
able for western blot and mRNA expression analysis. Nine of 34
(27%) BTC and 2 of 7 (29%) PSC bile samples were positive for
MUC4 protein, as compared to none of the 7 non-BTC malignancy
or 14 benign biliary condition samples (3 bile samples not
interpretable for MUC4 owing to nonspecific antibody detection).
This difference reached statistical significance for BTC (Po0.01)
but not for PSC (P¼0.06). Normalising bile samples according to
protein content (range: 1.3–5.2mgml
 1) did not affect the overall
outcome of the western blot analysis. There was no difference in
biliary MUC5AC and MUC5B expressions between the four disease
categories (Figure 2).
Median survival for BTC patients with MUC4-positive biliary
western blot result was 5.2 months (range: 1.3–26.6 months; 95%
CI: 4.6–5.8 months) compared with 11.8 months (range: 0.6–46.3
months; 95% CI: 7.8–15.2 months) for MUC4-negative BTC
patients (P¼0.30).
Biliary MUC4 and MUC5AC mRNA expression is raised in
PSC and biliary malignancy
Based on the Livak calculation (see Materials and Methods), there
was a 1.9-fold increase (95% CI: 1.69–2.33) in MUC4 mRNA
expression in BTC bile samples (n¼36) as compared to benign
biliary condition samples (n¼14; 95% CI: 0.86–1.16). This mRNA
signal in bile originated predominantly from biliary epithelial cells,
as shown by high CK-19 rather than CD45 gene expression
(Supplementary Figure). Bile samples from PSC (n¼7) and non-
BTC malignancy (n¼8) patients showed a 2.6-fold (95% CI: 2.21–
3.11) and 1.5-fold (95% CI: 1.18–1.88) increase in MUC4 mRNA
level over benign biliary conditions, respectively. The relative
increases of MUC4 mRNA expression levels in BTC, PSC and non-
BTC malignancies as compared to benign biliary conditions were
statistically significant (Pp0.05 for each; Figure 3).
MUC5AC mRNA was not detected in 13 of 65 bile samples (i.e.,
CT value 440; 6 normal, 6 BTC and 1 non-BTC malignancy
sample). For the remaining 52 bile samples, there was a 3.8-fold
increase (95% CI: 3.33–4.43) in MUC5AC mRNA expression level
in BTC bile samples (n¼30) as compared to benign biliary
condition samples (n¼8; 95% CI: 0.83–1.21). Bile samples from
PSC (n¼7) and non-BTC malignancy (n¼7) patients showed a
6.4-fold (95% CI: 4.75–8.61) and 1.9-fold (95% CI: 1.68–2.15)
increase, respectively, in MUC5AC mRNA level over benign biliary
conditions. The differences in relative MUC5AC mRNA expression
levels were statistically significant for BTC, PSC and non-BTC
malignancies as compared to benign biliary conditions, as well as
between the disease categories (Figure 3).
MUC5AC protein expression in serum is BTC specific
Sixty-six serum samples (92%) were available for western blot
analysis. Seventeen of 39 (44%) BTC and 1 of 7 (14%) PSC sera
were positive for MUC5AC protein as compared to none of the 5
non-BTC malignancy or 15 benign biliary disease serum samples.
This difference reached statistical significance for BTC (Po0.01)
but not for PSC (P¼0.26). Serum MUC4 protein was detected in 2
of 39 (5%) BTC patients, in 1 of 15 (7%) patients with benign
biliary disease and in none of the sera of PSC and non-BTC
malignancy patients. These differences were not statistically
significant (Figure 2).
The median survival (from time of BTC diagnosis) was 5.2
months (range: 0.3–31.7 months; 95% CI: 0.0–11.7 months) for
patients with MUC5AC-positive sera compared with 16.9 months
(range: 0.8–46.3 months; 95% CI: 9.8–23.9 months) for MUC5AC-
negative BTC patients (P¼0.03); the Kaplan–Meier survival
curves are shown in Figure 4.
Combining the serum MUC5AC expression with the biliary
MUC4 analysis resulted in a 14% increase in sensitivity but a 9%
decrease in specificity (Table 2). The accuracy of combined testing
was 69% (42 out of 61).
In patients with either biliary MUC4-positive or serum
MUC5AC-positive western blot results, the median survival was
6.8 months (range: 0.3–31.7 months; 95% CI: 3.0–10.6 months)
Table 1 Clinical characteristics of the 72 patients with biliary tract
strictures
BTC
(n¼39)
Non-BTC
(n¼33) P-value
Age (years)
a 67 (34–90) 59 (23–78) o0.01
b
Gender (female:male) 16:23 18:15 0.25
b
Ethnicity: Caucasian 95% (37/39) 85% (28/33) 0.75
b
Serum bilirubin (mmoll
 1)
a 119 (5–900) 20 (5–401) 0.01
b
Serum CA19-9 (IUl
 1)
a 493 (o1–80000) 52 (o1–1354) 0.03
b
Serum CEA (ngml
 1)
a 3.1 (0.6–155) 1.8 (0.8–12.3) 0.08
b
BTC topography (n¼39)
Perihilar CCA (Klatskin) 30 (77%)
Bismuth 4 18 (46%)
Bismuth 3 11 (28%)
Bismuth 2 1 (3%)
Extrahepatic CCA 5 (13%)
Gallbladder carcinoma 4 (10%)
BTC clinical T-stage
c
T2 2 (5%)
T3 22 (56%)
T4 15 (39%)
M1 5 (13%)
Non-BTC disease categories (n¼33)
Benign biliary conditions
d 18 (55%)
Non-BTC malignancies
e 8 (24%)
PSC 7 (21%)
BTC¼biliary tract cancer; CA¼carbohydrate antigen; CCA¼cholangiocarcinoma;
CEA¼carcinoembryonic antigen; PSC¼primary sclerosing cholangitis.
aValues are
median with ranges.
bStudent’s t-test (two-tailed, unequal variances) or w
2 test
applied.
cAssessment by means of imaging (pathological TNM stage available for one
patient) (AJCC, 2002).
dSeven inflammatory and one ischaemic strictures, five
sphincter-of-Oddi dysfunction and five choledocholithiasis.
eFour pancreatic cancer,
one adenocarcinoma of unknown primary, one ovarian cancer, one B-cell lymphoma
and one soft tissue spindle cell tumour.
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scompared with 17.6 months (range: 0.8–46.3 months; 95% CI:
8.4–26.8 months) for MUC4- and MUC5AC-negative BTC patients
(P¼0.06).
DISCUSSION
Alterations in epithelial mucin core protein and glycosylation play
a role in cellular growth, differentiation, invasion and immune
surveillance, and are known to influence metastases and survival
for a variety of cancers (Hollingsworth and Swanson, 2004).
However, there are few data, derived mainly from immunohisto-
chemistry studies, on mucin profile changes in BTC (Lee and Liu,
2001; Shibahara et al, 2004).
In the present study, we detected a strong association between
biliary MUC4 and serum MUC5AC protein expression and BTC.
None of the specimens from patients with benign, non-PSC biliary
BC
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Figure 2 Mucin protein expressions in bile, biliary tissue and serum of patients with biliary strictures (evaluated by presence and absence of staining). (A)
Western blotting of MUC4, MUC5AC and MUC5B expression in bile samples of BTC and non-BTC patients. MUC4 expression was more frequently seen
in bile of BTC patients (Po0.01). (B) Immunohistochemistry of MUC4, MUC5AC and MUC5B expression in BTC and benign biliary tissues. Again, MUC4
expression was more frequently seen in BTC tissues (P¼0.03). (C) Western blotting of MUC4 and MUC5AC expression in serum samples of BTC and
non-BTC patients. In serum, MUC5AC expression was statistically significantly more frequently seen in BTC patients (Po0.01), but no such association was
seen for MUC4 in serum.
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mRNA expression was highest in PSC, followed by BTC and non-BTC malignancies, with statistically significant differences between the disease categories
(Po0.05).
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either by western blot analysis or by immunohistochemistry.
Hence, MUC4 protein in bile and MUC5AC protein in serum are
both highly specific markers of BTC. We also detected increased
expressions of MUC4 and MUC5AC mRNA in BTC, although there
was some discrepancy between mucin protein and mRNA analyses
in bile. This may have been due to the greater sensitivity of real-
time RT–PCR or perhaps the difference in probe locations, which
were selected to be in regions not known to be prone to alternative
splicing, a common phenomena for MUC4 (Moniaux et al, 2000).
The two separate MUC4 antibodies used in this study detect
different regions of the glycoprotein: clone 1G8 recognises an
epitope from the transmembrane subunit, expected to be present
in association with cellular material, whereas clone 8G7 binds to
the extracellular tandem repeat domain, present in secretions.
However, the epitope may be made cryptic by post-translational
alterations including glycosylation, which differs between tissues
and may change in disease (Carlstedt et al, 1985; Hollingsworth
and Swanson, 2004). Although there is little tandem repeat
variation in MUC5AC, interindividual variation in MUC4 tandem
repeats and the unusually alkaline and detergent properties of bile
may have affected the sensitivity of epitope detection. However,
the lack of detection of MUC4 protein in normal bile and only low
levels of MUC4 RNA suggest that MUC4 is not synthesised to any
great extent in healthy biliary epithelial cells.
Membrane-associated mucins like MUC4 have become a focus
of interest, as they function as intrinsic ligands and modulate the
receptor tyrosine kinase ErbB2 (Carraway et al, 2003), an
antiapoptotic pathway used by most types of common epithelial
tumours (Yarden and Sliwkowski, 2001; Funes et al, 2006).
Therapeutic blockade of ErbB2 with the monoclonal antibody
trastuzumab improves the effectiveness of chemotherapy and
survival in breast cancer (Vogel et al, 2002). In human mammary
epithelial cells, MUC4 has an antiadhesive effect and appears to
promote tumour growth and progression (Pino et al, 2006; Singh
et al, 2007). In human pancreatic intraepithelial neoplasia, MUC4
expression increases progressively with advanced dysplasia
(Swartz et al, 2002), and inhibition of MUC4 by antisense RNA
suppresses cell growth and metastases in pancreatic cancer cells
(Singh et al, 2004; Moniaux et al, 2007). In other prospective BTC
serves, there was a trend towards reduced survival in patients with
MUC4-positive bile (5.0 vs 11.5 months). A similar survival
difference was described in a Japanese population undergoing
surgery for extrahepatic BTC (Tamada et al, 2006).
We demonstrated a 96% BTC-specificity for MUC5AC protein
detection in the serum of patients with biliary tract strictures. This
concurs well with results from the original Thai study (Wongkham
et al, 2003) and those from a subsequent ELISA-based study from
the same group, where serum MUC5AC positivity was associated
with reduced survival (Boonla et al, 2003; Bamrungphon et al,
2007). We detected a similar significant survival difference in our
study population. The relatively low level of MUC5AC positivity in
the archival tissue can be explained, in part, by the use of a less
sensitive MUC5AC antibody (monoclonal 21M1) for the immuno-
histochemistry. It is likely that the loss of cell orientation in
advanced neoplasia results in ‘spilling’ of the normally apically
secreted MUC5AC mucin into the circulation, which was then
detectable with the more sensitive polyclonal Lum5-1 antibody.
In the present study, the specificity for BTC detection of biliary
MUC4 and serum MUC5AC was superior to serum CA19-9: 93%
for biliary MUC4, 96% for serum MUC5AC and 65% for serum
CA19-9 (a value comparable with the published literature; Nehls
et al, 2004). This high specificity was, however, offset by
comparatively low sensitivity values of 27% for biliary MUC4
and 44% for serum MUC5AC. The sensitivity for BTC detection
increased to 58% by combining the biliary MUC4 and serum
MUC5AC data with a minor decrease in specificity (87%).
In conclusion, we have shown that in patients with biliary
obstruction, MUC4 expression in bile and MUC5AC expression in
serum are highly specific markers for BTC. The role of serum
MUC5AC as a non-invasive test for BTC, including in early-stage
disease, warrants further study. Targeting MUC4, with its
interaction with the oncoprotein ErbB2, may be a useful
therapeutic strategy in BTC.
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Figure 4 Kaplan–Meier survival curves of 39 consecutive BTC patients.
Patients with MUC5AC-positive serum had a lower median survival than
MUC5AC-negative patients (P¼0.03).
Table 2 BTC prediction markers for biliary MUC4, serum MUC5AC and
both mucin protein expressions combined on prospectively collected
clinical specimens
Biliary MUC4
(n¼62)
Serum MUC5AC
(n¼66)
Biliary MUC4 or
serum MUC5AC
(n¼61)
Sensitivity 27% (9/34) 44% (17/39) 58% (22/38)
Specificity 93% (26/28) 96% (26/27) 87% (20/23)
PPV 82% (9/11) 94% (17/18) 88% (22/25)
NPV 51% (26/51) 54% (26/48) 56% (20/36)
BTC¼biliary tract cancer; NPV¼negative predictive value; PPV¼positive predictive
value.
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